^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:ArteraAI Prostate Test
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
ArteraAIType:
Laboratory Developed Test
1m
Validation of a digital pathology-based multimodal artificial intelligence model in oliogmetastatic castration-sensitive prostate cancer, including in patients from the STOMP and ORIOLE phase II randomized clinical trials. (ASCO 2024)
We have shown for the first time that the ArteraAI MMAI biomarker is prognostic for OS in patients with omCSPC. Further, MMAI appears to be predict benefit of MDT with high MMAI demonstrating a greater improvement in MFS following MDT over observation. Further work in validating these findings is warranted to allow for greater personalization in the management of patients with omCSPC.
P2 data • Clinical • Metastases
|
ArteraAI Prostate Test
1m
Advancing Precision Oncology with Artificial Intelligence: Ushering in the ArteraAI Prostate Test. (PubMed, Urology)
No abstract available
Journal
|
ArteraAI Prostate Test
2ms
Artificial intelligence Steering Testosterone deprivation Treatments in prostate cancer External-beam radiotherapy (ASTuTE) (ANZCTR)
P=N/A | N=800 | Recruiting | Sponsor: GenesisCare | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2023
Enrollment open • Trial initiation date
|
ArteraAI Prostate Test
3ms
ArteraAI Announced as the First-and-Only Predictive Test for Therapy Personalization in the 2024 NCCN Guidelines for Prostate Cancer (Businesswire)
"ArteraAI...announced today its inclusion in the newly released NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer. The ArteraAI Prostate Test is the only test included for its predictive performance. The test is also the first AI-enabled predictive and prognostic test to be recommended in the guidelines for localized prostate cancer."
NCCN guideline
|
ArteraAI Prostate Test
Share
